Last reviewed · How we verify
NCT05937529
Impact of Madecassoside and 5 % Panthenol Cream in Post Photodynamic Therapy for Actinic Keratosis
NA trial testing Cream containing madecassoside and 5 % panthenol in Actinic Keratoses in 20 participants. Completed in 29 February 2024.
29 February 2024
Quick facts
| Lead sponsor | Merete Haedersdal |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 27 September 2023 |
| Primary completion | 29 February 2024 |
| Estimated completion | 29 February 2024 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Cream containing madecassoside and 5 % panthenol
- Daylight PDT
Conditions studied
- Actinic Keratoses — all drugs for Actinic Keratoses →
Sponsor
Merete Haedersdal — full company profile →
Who can join
Adults 18 to 100, any sex, with Actinic Keratoses. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Premalignant AKs are highly frequent in the light-skinned populations with an increasing incidence. PDT is considered a well-establish treatment for these lesions, and therefore it is essential to achieve an optimal and effective treatment as possible. The present study proposes a new post-treatment modality with application of an anti-inflammatory moisturizer Cicaplast Baume B5+ to the treated areas that may improve the overall patient satisfaction and minimize the local skin reactions. Treatment regime consists of two daily applications of Cicaplast Baume B5+ for 14 days, and this regime is not associated with increased risk of systemic AEs or serious events.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Clinical Measurement of Transepidermal Water Loss.
Kundu D, Jayaraman A, Sen CK. · · 2026 · cited 4× · PMID 40476522 · DOI 10.1089/wound.2024.0148 -
The Effect of Myc Inhibition Combined with the Synergistic Effect of Photothermal, Photodynamic and Radiotherapy in Tumor Treatment.
Cui Y, Yang W, Liu W, Li Y, et al · · 2025 · PMID 41103361 · DOI 10.2147/ijn.s526592
Verify or expand the search:
- PubMed search for NCT05937529
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Actinic Keratoses
Currently open trials in the same condition.
- NCT06499415 — Combination Therapy of 5-Fluorouracil and CALcipotriol Versus 5-Fluorouracil in the Treatment of Actinic Keratosis · Phase 4 · recruiting
- NCT06385340 — Investigation of the Effect of Lipikar Baume AP+M · NA · recruiting
- NCT06321003 — SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography · recruiting
- NCT05202860 — Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients with Actinic Keratosis · Phase 2 · active not recruiting
- NCT05976061 — High- and Low-risk Actinic Keratosis Referrals to Secondary Care · active not recruiting
Other Merete Haedersdal trials
Trials by the same sponsor.
- NCT05461755 — Treatment of Striae Distensae With Fractional Radiofrequency and Topical Tretinoin · Phase 2 · completed
- NCT05202860 — Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients with Actinic Keratosis · Phase 2 · active not recruiting
- NCT05057117 — Longevity of Microwave Thermolysis and Botulinum Toxin A for Treatment of Axillary Hyperhidrosis · Phase 4 · completed
- NCT04221126 — TMFI Enhances Skin Surface and Epidermal PpIX Fluorescence · Phase 4 · completed
- NCT03573076 — Treatment of Photodamaged Skin of the décolleté · Phase 4 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05937529 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Merete Haedersdal
- Last refreshed: 8 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05937529.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing